ABUS
Arbutus Biopharma CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$871.83M
P/E Ratio
—
EPS
$-0.17
Beta
0.74
52W High
$5.10
52W Low
$2.71
50-Day MA
$4.33
200-Day MA
$4.15
Dividend Yield
—
Profit Margin
-237.90%
Forward P/E
10.25
PEG Ratio
0.00
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Fundamentals
| Revenue (TTM) | $14.08M |
| Gross Profit (TTM) | $-11.16M |
| EBITDA | $-26.69M |
| Operating Margin | -727.00% |
| Return on Equity | -38.50% |
| Return on Assets | -14.90% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.40 |
| Price-to-Book | 11.46 |
| Price-to-Sales (TTM) | 61.91 |
| EV/Revenue | 55.88 |
| EV/EBITDA | 2.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -33.20% |
| Shares Outstanding | $195.48M |
| Float | $127.68M |
| % Insiders | 21.45% |
| % Institutions | 63.51% |
Data last updated: 4/7/2026